Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Yoshinobu Hirayama"'
Autor:
Sanae Fukuda, Hidenori Koyama, Kazuhiro Kondo, Hisako Fujii, Yoshinobu Hirayama, Tsutomu Tabata, Mikio Okamura, Tomoyuki Yamakawa, Shigeki Okada, Sumio Hirata, Hiroshi Kiyama, Osami Kajimoto, Yasuyoshi Watanabe, Masaaki Inaba, Yoshiki Nishizawa
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119578 (2015)
Fatigue is a predictor of cardiovascular events in patients with end-stage renal disease (ESRD) undergoing hemodialysis treatment. We hypothesized that multinutritional support would improve quality of life, fatigue symptoms, and potential quantitati
Externí odkaz:
https://doaj.org/article/800e6f099d2f4032b52b163ee2cca53b
Autor:
Yasuyoshi Watanabe, Hisako Fujii, Hidekichi Tokai, Tetsuo Shoji, Jun-ichi Koizumi, Kouji Yamaguti, Hirohiko Kuratsune, Hidenori Koyama, Sanae Fukuda, Yoshinobu Hirayama, Seiki Tajima, Masaaki Inaba, Yoshiki Nishizawa
Publikováno v:
Journal of Renal Nutrition. 23:340-347
Objective In the present study, we assessed the associations among fatigue, quality of life (QOL), clinical parameters, and body mass index (BMI) with autonomic function in end-stage renal disease (ESRD) patients undergoing hemodialysis as well as fa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aea84e11ad936b9faf895a084eae27f9
https://doi.org/10.1053/j.jrn.2012.12.008
https://doi.org/10.1053/j.jrn.2012.12.008
Autor:
Masaaki Inaba, Yoshinobu Hirayama, Kazuhiro Kondo, Sumio Hirata, Hidenori Koyama, Osami Kajimoto, Hiroshi Kiyama, Tomoyuki Yamakawa, Yasuyoshi Watanabe, Sanae Fukuda, Tsutomu Tabata, Shigeki Okada, Mikio Okamura, Yoshiki Nishizawa, Hisako Fujii
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0119578 (2015)
PLoS ONE
PLoS ONE
Background Fatigue is a predictor of cardiovascular events in patients with end-stage renal disease (ESRD) undergoing hemodialysis treatment. We hypothesized that multinutritional support would improve quality of life, fatigue symptoms, and potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0db7c1b1b3e4351064a3c1cfed7c2828
http://europepmc.org/articles/PMC4352065?pdf=render
http://europepmc.org/articles/PMC4352065?pdf=render
Autor:
Yoshinobu Hirayama
Publikováno v:
YAKUGAKU ZASSHI. 131:877-879
We need the surroundings in which we can conduct sciences-based safety measurements and continue to do scientific approach in order to ensure the safety of drugs and put patients and the nation at ease. It is important that we actively conduct clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c48d43f54cc560eb1b9902788b768a
https://doi.org/10.1248/yakushi.131.877
https://doi.org/10.1248/yakushi.131.877
Autor:
Yoshinobu Hirayama
Publikováno v:
Drug Metabolism and Pharmacokinetics. 14:227-230
Outlines of two guidelines related to pharmacokinetics of guidelines recently adopted in ICH, general guideline (E8) and timing guideline (W), were explained. Both guidelines show that exposure data in animals should be evaluated prior to human clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3a15b7f6503092833fea63331331542
https://doi.org/10.2133/dmpk.14.227
https://doi.org/10.2133/dmpk.14.227
Autor:
Yoshinobu Hirayama
Publikováno v:
Drug Information Journal. 32:111-117
On the basis of the discussion at the Committee for Drug Safety Ensuring Measures, the Japanese Ministry of Health and Welfare (MHW) has amended the Pharmaceutical Affairs Law (PAL) and related laws, and is reforming its review system for new drugs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f48a68c6feb99c6841a5526ee12cc824
https://doi.org/10.1177/009286159803200115
https://doi.org/10.1177/009286159803200115
Autor:
Yoshinobu, Hirayama
Publikováno v:
Asian Pacific journal of cancer prevention : APJCP. 11(1)
In Japan, for medicines we have the Pharmaceutical Affairs Law and for food the Food Sanitation Law, these two being applied appropriately for security management. The range of test data needed to be obtained by examination is prescribed by the laws,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::95a2e365a7c3b0fa9871feabd3522356
https://pubmed.ncbi.nlm.nih.gov/20593923
https://pubmed.ncbi.nlm.nih.gov/20593923
Autor:
Tsutomu Tabata, Hirohiko Kuratsune, Tomoyuki Yamakawa, Mikio Okamura, Yasuyoshi Watanabe, Masaaki Inaba, Hidenori Koyama, Hisako Fujii, Yoshiki Nishizawa, Shigeki Okada, Yoshinobu Hirayama, Yoshihiro Tsujimoto, Senji Okuno, Sanae Fukuda, Tetsuo Shoji
Publikováno v:
Clinical journal of the American Society of Nephrology : CJASN. 5(4)
Background and objectives: Despite potential significance of fatigue and its underlying components in the occurrence of cardiovascular diseases, epidemiologic data showing the link are virtually limited. This study was designed to examine whether fat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4db96f092b7eb632a47edc697a315a25
https://pubmed.ncbi.nlm.nih.gov/20185601
https://pubmed.ncbi.nlm.nih.gov/20185601
Autor:
Yoshinobu Hirayama
Publikováno v:
Improving the Regulatory Review Process: Assessing Performance and Setting Targets ISBN: 9789401060424
1. Reform is under way in all stages of the drug approval process in Japan. Following a 2-year review, the Ministry of Health and Welfare (MHW) has amended the Pharmaceutical Affairs Law and related laws. 2. The reforms will strengthen the MHW’s ro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90fe9ece7b6b4f88d854e5710ac32e1e
https://doi.org/10.1007/978-94-011-4874-0_4
https://doi.org/10.1007/978-94-011-4874-0_4
Autor:
Yoshinobu Hirayama
Publikováno v:
Drug Metabolism and Pharmacokinetics. 13:142-143
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::591f03602964c700508654da9858c867
https://doi.org/10.2133/dmpk.13.supplement_142
https://doi.org/10.2133/dmpk.13.supplement_142